
Sign up to save your podcasts
Or


When the very treatment keeping a patient alive also exacts a heavy toll on lives, researchers are compelled to ask, “Is there another way?”
Glioblastoma is a brutal brain cancer. It is aggressive, common and nearly always fatal. Standard treatments of radiation and chemotherapy often leave patients with cognitive problems and a diminished quality of life.
But Dr. Macarena de la Fuente, chief of the Neuro oncology Division at Sylvester Comprehensive Cancer Center, envisions a future that empowers patients to manage tumors with fewer compromises. She investigates new drugs that prolong progression-free survival and delay the need for toxic treatments.
In some of the clinical trials she and her team are advancing, the tumors even shrank in size.
By University of Miami Miller School of MedicineWhen the very treatment keeping a patient alive also exacts a heavy toll on lives, researchers are compelled to ask, “Is there another way?”
Glioblastoma is a brutal brain cancer. It is aggressive, common and nearly always fatal. Standard treatments of radiation and chemotherapy often leave patients with cognitive problems and a diminished quality of life.
But Dr. Macarena de la Fuente, chief of the Neuro oncology Division at Sylvester Comprehensive Cancer Center, envisions a future that empowers patients to manage tumors with fewer compromises. She investigates new drugs that prolong progression-free survival and delay the need for toxic treatments.
In some of the clinical trials she and her team are advancing, the tumors even shrank in size.